The Edwards Lifesciences Corporation (EW) - Investment Analysts' Weekly Ratings Updates

Postado Agosto 14, 2017

Edwards Lifesciences Corporation (EW) traded down 1.323% during midday trading on Wednesday, reaching $113.745. Shine Investment Advisory Services Inc. bought a new position in shares of Edwards Lifesciences Corporation during the second quarter worth about $126,000. SunTrust Banks also issued estimates for Edwards Lifesciences Corporation's Q3 2017 earnings at $0.83 EPS, FY2017 earnings at $3.55 EPS, Q1 2018 earnings at $1.09 EPS, Q2 2018 earnings at $0.99 EPS, Q3 2018 earnings at $0.93 EPS, Q4 2018 earnings at $1.05 EPS, FY2018 earnings at $4.06 EPS, FY2019 earnings at $4.63 EPS, FY2020 earnings at $5.21 EPS and FY2021 earnings at $5.71 EPS.

Several brokerages recently commented on EW. Quadrant Capital Group LLC increased its position in Edwards Lifesciences Corporation by 3.5% in the first quarter. The stock has a 50-day moving average of $116.95 and a 200 day moving average of $105.35. Edwards Lifesciences Corporation comprises 0.6% of Mandatum Life Insurance Co Ltd's holdings, making the stock its 12th largest position. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. NEXT Financial Group Inc now owns 1,045 shares of the medical research company's stock worth $115,000 after buying an additional 500 shares during the last quarter.

Nippon Life Global Investors Americas Inc. increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 69.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,300 shares of the medical research company's stock at the end of the second quarter. During the same period in the previous year, the business earned $0.76 earnings per share. Macquarie Group Ltd. now owns 149,380 shares of the medical research company's stock valued at $13,996,000 after buying an additional 54,196 shares during the last quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company's stock valued at $109,000 after buying an additional 41 shares during the last quarter. Canaccord Genuity restated a "buy" rating and set a $155.00 price objective (up from $150.00) on shares of Edwards Lifesciences Corporation in a research note on Sunday, July 30th. The First American Bank holds 104,089 shares with $9.75M value, down from 110,372 last quarter. The firm has a market cap of $23.99 billion, a PE ratio of 38.02 and a beta of 0.64. Institutional investors own 84.15% of the company's stock.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 26th. IBM Retirement Fund boosted its position in shares of Edwards Lifesciences Corporation by 116.4% in the second quarter. Vetr cut Edwards Lifesciences Corporation from a "strong-buy" rating to a "buy" rating and set a $124.67 price objective for the company.in a research report on Monday, May 15th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million for the quarter, compared to analysts' expectations of $839.16 million. Renaissance Technologies Llc sold 611,206 shares as Edwards Lifesciences Corp (EW)'s stock rose 25.80%. Equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Stock Observer and is the property of of Stock Observer. The business's revenue was up 10.9% compared to the same quarter past year. Jefferies Group LLC reaffirmed a buy rating on shares of Edwards Lifesciences Corporation in a research note on Wednesday, April 26th. If you are viewing this piece on another site, it was illegally copied and reposted in violation of US & worldwide trademark & copyright legislation. They set a "conviction-buy" rating and a $138.00 target price for the company. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. The stock now has an average rating of "Buy" and an average target price of $121.13. It also upped Suncoke Energy Inc (NYSE:SXC) stake by 555,689 shares and now owns 2.86M shares.

In other Edwards Lifesciences Corporation news, VP Patrick B. Verguet sold 11,500 shares of the business's stock in a transaction on Monday, May 15th. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The stock's average target of $96 is -16.46% below today's ($114.91) share price. The shares were sold at an average price of $111.64, for a total transaction of $1,283,860.00.

In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 32,900 shares of the business's stock in a transaction dated Wednesday, June 7th. The disclosure for this sale can be found here. Insiders sold a total of 183,412 shares of company stock valued at $21,176,230 over the last 90 days.

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and fix products used to replace or fix a patient's diseased or defective heart valve. The Firm is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.